Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT01076322 | A Study to Evaluate the Efficacy and Safety of Meptin® Swinghaler® and Ventolin® MDI in Stable Asthma Patients | PHASE3 | COMPLETED | 17 | — | — | Mar 1, 2009 | Jun 1, 2010 | Aug 12, 2010 | 1 | Taiwan |
| Arm | Type | Description |
|---|---|---|
| Treatment-A sequence | EXPERIMENTAL | Meptin® Swinghaler / Ventolin® MDI |
| Treatment-B sequence | EXPERIMENTAL | Ventolin® MDI / Meptin® Swinghaler |
| Name | Type | Description |
|---|---|---|
| Meptin® Swinghaler | DRUG | Meptin® Swinghaler® * Ingredient: Procaterol HCL * Dosage form: 10g/puff * Dose(s): 10g * Dosing schedule: 20g (total 20g) |
| Ventolin® MDI | DRUG | Ventolin® MDI * Ingredient: Salbutamol sulfate * Dosage form: 100g/puff * Dose(s): 100g * Dosing schedule: 200g (total 200g) |
Inclusion Criteria: 1. Male or females outpatients aged ≥ 16 years old with stable mild to moderate persistent asthma; Stability was assessed the patient remained in the same severity class (mild, moderate) and had no acute exacerbations by investigator judgment during the past 14 days; 2. Pulmonar...